Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
272.64
-4.69 (-1.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
September 07, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
September 05, 2023
Via
Benzinga
The Latest Analyst Ratings for Alnylam Pharmaceuticals
August 16, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
July 25, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
June 22, 2023
Via
Benzinga
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
August 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
August 03, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
June 21, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
June 16, 2023
Via
Benzinga
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
July 31, 2023
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key
Via
Benzinga
Lululemon Athletica To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
July 25, 2023
Needham raised the price target for F5, Inc. (NASDAQ: FFIV) from $175 to $180. Needham analyst Alex Henderson maintained a Buy rating. F5 shares jumped 11.2% to $167.00 in pre-market trading.
Via
Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
July 24, 2023
Wall Street Journal
Via
Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
July 24, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to
Via
Benzinga
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
July 24, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Shares of BridgeBio Pharma Skyrocketed This Week
July 21, 2023
The biotech company saw strong results in a phase 3 trial.
Via
The Motley Fool
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
July 20, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
July 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Alnylam Pharmaceuticals Topped the Market Today
July 17, 2023
Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.
Via
The Motley Fool
Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars
July 17, 2023
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and
Via
Benzinga
BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease
July 17, 2023
The companies are working on treatments for a leading cause of heart failure.
Via
Investor's Business Daily
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
July 17, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
July 14, 2023
Via
Benzinga
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
June 30, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
June 09, 2023
Via
Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
June 07, 2023
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by
Via
Benzinga
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.